Having established itself as a main player in gene therapy, with Zolgensma for spinal muscular atrophy closing in on blockbuster status, Novartis AG is targeting inherited eye diseases with its acquisition of US optogenetics specialist Vedere Bio.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?